Simplex Trading
ADMA icon

Simplex Trading’s ADMA Biologics ADMA Stock Holding History

Simplex Trading’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.42M Buy
268,600
+47,700
+22% +$753K ﹤0.01% 1674
2025
Q4 		$4.03M Buy
220,900
+87,000
+65% +$1.47M ﹤0.01% 1451
2025
Q3 		$1.96M Sell
133,900
-5,100
-4% -$87.4K ﹤0.01% 2345
2025
Q2 		$2.53M Buy
139,000
+500
+0.4% +$10.2K ﹤0.01% 1902
2025
Q1 		$2.75M Sell
138,500
-8,200
-6% -$142K ﹤0.01% 1743
2024
Q4 		$2.52M Sell
146,700
-17,300
-11% -$325K ﹤0.01% 1999
2024
Q3 		$3.28M Sell
164,000
-35,700
-18% -$555K ﹤0.01% 1847
2024
Q2 		$2.23M Buy
199,700
+77,800
+64% +$653K ﹤0.01% 2092
2024
Q1 		$804K Buy
121,900
+88,800
+268% +$485K ﹤0.01% 3352
2023
Q4 		$149K Buy
33,100
+25,600
+341% +$94.7K ﹤0.01% 4981
2023
Q3 		$26K Sell
7,500
-114,200
-94% -$440K ﹤0.01% 6375
2023
Q2 		$449K Sell
121,700
-146,800
-55% -$544K ﹤0.01% 3423
2023
Q1 		$888K Sell
268,500
-73,100
-21% -$253K ﹤0.01% 2697
2022
Q4 		$1.32M Buy
341,600
+72,800
+27% +$225K ﹤0.01% 2204
2022
Q3 		$653K Buy
268,800
+160,200
+148% +$384K ﹤0.01% 3148
2022
Q2 		$215K Buy
108,600
+47,000
+76% +$92.5K ﹤0.01% 4511
2022
Q1 		$112K Sell
61,600
-19,500
-24% -$30.4K ﹤0.01% 5980
2021
Q4 		$114K Buy
81,100
+21,500
+36% +$28.3K ﹤0.01% 6038
2021
Q3 		$94K Sell
59,600
-100
-0.2% -$140 ﹤0.01% 6701
2021
Q2 		$95K Buy
59,700
+58,977
+8,157% +$104K ﹤0.01% 6795
2021
Q1 		$127K Sell
723
-730
-50% -$1.67K ﹤0.01% 5407
2020
Q4 		$283K Buy
1,453
+1,115
+330% +$2.34K ﹤0.01% 4155
2020
Q3 		$80K Sell
338
-375
-53% -$1.03K ﹤0.01% 5130
2020
Q2 		$208K Sell
713
-1,721
-71% -$4.95K ﹤0.01% 3948
2020
Q1 		$700K Buy
2,434
+2,418
+15,113% +$8.36K ﹤0.01% 2245
2019
Q4 		$6K Sell
16
-385
-96% -$1.68K ﹤0.01% 6597
2019
Q3 		$178K Buy
401
+267
+199% +$1.12K ﹤0.01% 3682
2019
Q2 		$51K Buy
134
+16
+14% +$71 ﹤0.01% 4842
2019
Q1 		$44K Buy
+118
New +$417 ﹤0.01% 5105

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Simplex Trading's ADMA Position: Q1 2026 in Review

Simplex Trading opened a new position in ADMA Biologics (ADMA) in Q1 2026: 54,917 shares worth $495K. The stake represents ﹤0.01% of the portfolio and ranks #3277 among its holdings. This is a return to the name: Simplex Trading previously reported a position in ADMA as recently as Q3 2025.

Simplex Trading first reported a position in ADMA in Q3 2018 and has held it in 16 quarters since. The position peaked at $774K in Q3 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Simplex Trading held 54,917 shares of ADMA Biologics worth $495K as of Q1 2026.
  • ADMA Biologics was a new Simplex Trading position in Q1 2026.
  • ADMA Biologics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #3277 holding.
  • Simplex Trading first reported a position in ADMA Biologics in Q3 2018 and has held it in 16 quarters since.
  • Simplex Trading's ADMA Biologics position peaked at $774K in Q3 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.